Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
0% citation coverage
This week's Friday Five covers standout data from ASCO 2025, including Revolution Medicines' pancreatic cancer results, a preview of the upcoming ADA meeting, and a significant Eli Lilly deal in China. The roundup also highlights ADC safety findings and a new BMS-Hengrui collaboration, providing decision-useful insights for pharma stakeholders.
Intelligence Snapshot
Executive Summary
Revolution Medicines' pancreatic cancer data was a standout at ASCO news 2025, earning a standing ovation.
Key Insights
-
A real-world study revealed serious blood-related side effects from ADCs, raising safety…
A real-world study revealed serious blood-related side effects from ADCs, raising safety concerns.
-
Eli Lilly and BMS each announced new deals in China, signaling a shift toward…
Eli Lilly and BMS each announced new deals in China, signaling a shift toward collaboration with Chinese biotechs.
- All eyes are now on the upcoming ADA meeting for metabolic disease updates.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Quick Answer
Revolution Medicines' pancreatic cancer data was a standout at ASCO news 2025, earning a standing ovation.
Key Questions
- What was the biggest news at ASCO 2025?
- What are the safety concerns with ADCs?
- What new deals were announced in China?
- What should investors watch at the ADA meeting?
- Where can I find more ASCO 2025 analysis?
Executive Scorecard
Heuristic scores · directional, not investment adviceContents8 sections
Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
This week's Friday Five covers standout data from ASCO 2025, including Revolution Medicines' pancreatic cancer results, a preview of the upcoming ADA meeting, and a significant Eli Lilly deal in China. The roundup also highlights ADC safety findings and a new BMS-Hengrui collaboration, providing decision-useful insights for pharma stakeholders.
IntelligenceRegulatory Impact
the FDA and EMA are the bodies to watch. Regulatory relevance reads high for this therapeutic area. Teams should track submission types, designations, and any guidance shifts that could move approval timelines.
Key Takeaways
- Revolution Medicines' pancreatic cancer data was a standout at ASCO news 2025, earning a standing ovation.
- A real-world study revealed serious blood-related side effects from ADCs, raising safety concerns.
- Eli Lilly and BMS each announced new deals in China, signaling a shift toward collaboration with Chinese biotechs.
- All eyes are now on the upcoming ADA meeting for metabolic disease updates.
IntelligenceCompetitive Intelligence
Competitive pressure is medium. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.
What Made ASCO 2025 a Standout for Pancreatic Cancer?
The American Society of Clinical Oncology (ASCO) 2025 meeting delivered several high-impact readouts. Revolution Medicines presented promising pancreatic cancer data, earning a standing ovation over the weekend. The data underscores a potential shift in treatment for one of oncology's toughest indications. Separately, a major real-world study published at the meeting found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of cancer therapies. The findings raise new questions about the safety profile of ADCs, which have been a major focus for big pharma pipelines and dealmaking.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high. Expect implications for this therapeutic area pricing, access, and launch sequencing.
Why Are China Deals Accelerating for Lilly and BMS?
The dealmaking momentum in China continued apace. Eli Lilly secured a new collaboration with a Chinese biotech, reflecting a broader trend of Western pharma tapping into Chinese innovation. Bristol Myers Squibb also inked a partnership with Hengrui Pharma, a move reminiscent of another recent BMS-Hengrui deal that signals a more collaborative approach to working with Chinese companies. For BD teams, these transactions highlight the growing importance of China as a source of early-stage assets and a market for global launches.
IntelligenceStrategic Takeaways
Revolution Medicines' pancreatic cancer data was a standout at ASCO news 2025, earning a standing ovation. A real-world study revealed serious blood-related side effects from ADCs, raising safety concerns. Eli Lilly and BMS each announced new deals in China, signaling a shift toward collaboration with Chinese biotechs.
What Should You Watch at the ADA Meeting?
The industry now turns to the American Diabetes Association (ADA) meeting, which will be a key catalyst for diabetes and obesity assets. Investors and analysts should watch for updates on GLP-1 receptor agonists, combination therapies, and next-generation metabolic drugs. The ADA meeting will likely reshape competitive dynamics in the metabolic disease space, especially as Eli Lilly and Novo Nordisk continue to jockey for market share.
IntelligenceEvidence Quality
This analysis is backed by 0% citation coverage. Confidence reflects source provenance and editorial review.
Implications for Pharma Teams
For BD teams, the ASCO data and China deals signal new opportunities in oncology and metabolic diseases. Investors should watch Revolution Medicines' stock and ADC safety developments, which could impact the ADC pipeline. The ADA meeting will be a key catalyst for diabetes and obesity assets. Analysts should track how these deals reshape competitive dynamics, especially in the China market.
Frequently Asked Questions
What was the biggest news at ASCO 2025?
Revolution Medicines' pancreatic cancer data was a standout, earning a standing ovation at the meeting. The data suggests a potential new treatment option for a disease with historically poor outcomes.
What are the safety concerns with ADCs?
A real-world study presented at ASCO 2025 found serious blood-related side effects associated with antibody-drug conjugates. This raises questions about the risk-benefit profile of these drugs, which have been a major focus of pharma R&D and dealmaking.
What new deals were announced in China?
Eli Lilly and Bristol Myers Squibb each announced new collaborations with Chinese biotechs. BMS's deal with Hengrui Pharma signals a more collaborative approach to working with Chinese companies, a trend that is reshaping the global pharma landscape.
What should investors watch at the ADA meeting?
Investors should watch for updates on GLP-1 receptor agonists, combination therapies, and next-generation metabolic drugs. The ADA meeting will be a key catalyst for diabetes and obesity assets, which have been a major focus for big pharma.
Where can I find more ASCO 2025 analysis?
For more detailed analysis, FirstWord Pharma provides in-depth coverage of ASCO 2025 takeaways, including Revolution Medicines' data, ADC safety findings, and China deal flow.
Related coverage
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Sources analyzed
- 1
- Evidence strength
- 44/100
- Last verified
- Jun 6, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Limited source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
